Mazdutide Research
Home › Blog › Mazdutide Guide
Weight LossMetabolism⏱ 11 min read

Mazdutide: The Dual GLP-1/Glucagon Agonist for Metabolic Efficiency Research

Mazdutide (IBI362) is a next-generation co-agonist discovered through oxyntomodulin research. By targeting both the satiety pathways of GLP-1 and the fat-burning pathways of glucagon, research highlights its ability to drive weight loss exceeding 15%.

By Nūmira Research TeamUpdated: May 2026
Buy Mazdutide →

What is Mazdutide?

Mazdutide is a synthetic peptide based on the structure of **oxyntomodulin**, a naturally occurring human hormone that activates both the GLP-1 and glucagon receptors. It was optimized for a weekly dosing schedule, making it a leading candidate in the race for "next-gen" metabolic therapies.

In Phase 3 clinical trials (such as the GLORY-1 study), Mazdutide has consistently demonstrated weight-loss efficacy that surpasses traditional GLP-1 monotherapies, marking it as a significant focus for researchers in the field of obesity and type 2 diabetes.

⚗️ Key Research Facts

  • Research Code: IBI362
  • Type: Dual GLP-1R and GCGR Agonist
  • Molecular Basis: Oxyntomodulin Derivative
  • Phase: Phase 3 Completed (Primary Endpoints Met)

Mechanism: Satiety & Energy Expenditure

Mazdutide’s "dual-agonist" design provides a two-pronged attack on metabolic dysfunction:

  • GLP-1R Agonism: Targets the hypothalamus to increase feelings of fullness (satiety) and slows gastric emptying, leading to reduced caloric intake.
  • Glucagon Receptor (GCGR) Agonism: Increases the body's basal metabolic rate, enhances fatty acid oxidation (lipolysis), and promotes energy expenditure.

This combination is crucial because pure caloric restriction (standard dieting) often slows the metabolism. Mazdutide research shows it can help prevent this metabolic "slowdown" by keeping energy expenditure high.

Clinical Research Results (GLORY-1)

The **GLORY-1** Phase 3 trial was a landmark study for Mazdutide. The results were highly significant:

14.4% Weight Loss

Subjects receiving the 6 mg dose lost an average of 14.4% of their body weight over 48 weeks.

Significant Waist Reduction

Participants saw a massive reduction in waist circumference, indicating a loss of dangerous visceral fat.

Liver & Metabolic Health Benefits

Beyond weight loss, Mazdutide has shown a profound ability to reduce **liver fat**. In research subjects with fatty liver disease, Mazdutide administration led to a substantial decrease in hepatic lipid content, improved blood pressure, and lower uric acid levels.

Research Protocols & Dosing

💡 Research Note: Mazdutide is uniquely effective at lower doses (6 mg to 9 mg) compared to other multi-agonists.
  • Administration: Once-weekly subcutaneous injection.
  • Research Dose: 3 mg, 6 mg, or 9 mg.
  • Safety: Side effects are primarily gastrointestinal (nausea) and typically subside within the first few weeks of research.
  • Storage: Lyophilized powder in the freezer. Reconstituted solution in the refrigerator.

Frequently Asked Questions

How is it different from Semaglutide?

Semaglutide is a single agonist (GLP-1). Mazdutide is a dual agonist (GLP-1 + Glucagon). The addition of glucagon is intended to increase the amount of calories the body burns at rest, which may lead to more rapid or sustained weight loss in research models.

Does it help with Type 2 Diabetes?

Yes. Research trials have shown it to be highly effective at lowering HbA1c levels and improving insulin sensitivity in diabetic research subjects.

Where to buy Mazdutide in Canada?

Nūmira Peptides offers high-purity Mazdutide (IBI362) for laboratory and scientific research. Shop Mazdutide →

Mazdutide Canada

Mazdutide — Research Grade

Purity >98% · Dual GLP-1/Glucagon · Domestic Canadian shipping

Shop Mazdutide →